Further studies are necessary to evaluate the therapeutic effectiveness of the combination of mIDH inhibitors with hypomethylating drugs and the inhibitors of tyrosine kinase, mTORC1, OxPHOS, GLS, Nrf2, PARP and BCL-2, in AML therapy. This evidence concerns the gene BCL2 and acute myeloid leukemia.